Retinal vascular occlusion and SARS-CoV-2 vaccination.
Adult
Humans
Angiogenesis Inhibitors
COVID-19
/ epidemiology
COVID-19 Vaccines
/ adverse effects
Fluorescein Angiography
Intravitreal Injections
Retinal Diseases
/ drug therapy
Retinal Vein Occlusion
/ etiology
Retrospective Studies
SARS-CoV-2
Tomography, Optical Coherence
Treatment Outcome
Vaccination
COVID-19
COVID-19 vaccination
Retinal imaging
Retinal vascular occlusion
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
10
02
2022
accepted:
14
05
2022
revised:
26
04
2022
pubmed:
26
5
2022
medline:
22
10
2022
entrez:
25
5
2022
Statut:
ppublish
Résumé
To assess the clinical and retinal imaging features of patients in whom retinal vascular occlusion (VO) had developed in temporal associations with COVID-19 vaccination. In this retrospective case series, all consecutive adult patients with new onset VO within 6 weeks of vaccination against COVID-19 were included in the study between May 1 and October 31, 2021. All patients had a systemic medical health assessment, full ophthalmic evaluation, and complete fundus imaging. Fifteen eyes of VO (14 patients) after COVID-19 vaccinations were identified. The median time between vaccination and symptoms onset was 14 days (range 7-42 days). The mean best-corrected visual acuity (BCVA) was 20/55 with a range of 20/20 to 20/200. Eleven of 15 eyes (73.3%) had visual acuity improvement after intravitreal treatment at 60-90 days (range, 45-105 days) from the presentation. Four of 5 cases without systemic risk factors for VO had a mean BCVA > 20/32 at presentation and > 20/25 at the latest evaluation. Between May 1 and October 31, 2021, a temporal association was found between the 15 reported cases and COVID-19 vaccination out of a total of 29 VO (p = 0.05). The incidence of VO was higher in the considered period compared to the equivalent 6-month period in 2019 (1.17% vs 0.52%, respectively; p = 0.0134). Retinal vascular occlusion with different grades of severity are reported in temporal association with COVID-19 vaccination. The exact pathogenic mechanism needs to be further studied. No certain causal relationship can be established from this case series.
Identifiants
pubmed: 35612613
doi: 10.1007/s00417-022-05707-5
pii: 10.1007/s00417-022-05707-5
pmc: PMC9130976
doi:
Substances chimiques
Angiogenesis Inhibitors
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3455-3464Informations de copyright
© 2022. The Author(s).
Références
Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615
doi: 10.1056/NEJMoa2034577
Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416
doi: 10.1056/NEJMoa2035389
Sadoff J, Gray G, Vandebosch A et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187–2201
doi: 10.1056/NEJMoa2101544
Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111
doi: 10.1016/S0140-6736(20)32661-1
Gao Q, Bao L, Mao H et al (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369(6499):77–81
doi: 10.1126/science.abc1932
Report Vaccini Anti COVID-19. Accessed 1 Nov 2021. https://www.governo.it/it/cscovid19/report-vaccini/
Sistema di accesso online ai dati delle segnalazioni di sospette reazioni averse registrate nella Rete Nazionale di Farmacovigilanza, Agenzia Italiana del Farmaco. Accessed 1 Nov 2021. https://bi.aifa.gov.it/SASVisualAnalyticsViewer/VisualAnalyticsViewer_guest.jsp?reportName=FVG_Intro0_report&reportPath=/Shared+Data/BI+FARMACOVIGILANZA/Public/Report/&appSwitcherDisabled=true .
Hayreh SS (2005) Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24(4):493–519
doi: 10.1016/j.preteyeres.2004.12.001
Centers for Disease Control and Prevention. COVID-19 testing overview. Updated March 17, 2021. Accessed 1 Nov 2021. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
Rapporto sulla Sorveglianza dei vaccini COVID-19, Agenzia Italiana del Farmaco. Accessed 1 Nov 2021. https://www.aifa.gov.it/documents/20142/1315190/Rapporto_sorveglianza_vaccini_COVID-19_9.pdf
Zhou JQ, Xu L, Wang S et al (2013) The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology 120(4):803–808
doi: 10.1016/j.ophtha.2012.09.033
Sacconi R, Simona F, Forte P et al (2022) Retinal vein occlusion following two doses of mRNA-1237 (moderna) immunization for SARS-cov-2: a case report. Ophthalmol Ther 11(1):453–458
doi: 10.1007/s40123-021-00441-3
Endo B, Bahamon S, Martínez-Pulgarín D (2021) Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: a case report. Indian J Ophthalmol 69(10):2865–2866
doi: 10.4103/ijo.IJO_1477_21
Bialasiewicz AA, Farah-Diab MS, Mebarki HT (2021) Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine. Int Ophthalmol 41(12):3889–3892
doi: 10.1007/s10792-021-01971-2
Shah PP, Gelnick S, Jonisch J, et al. Central retinal vein occlusion following BNT162b2 (Pfizer-BioNTech) COVID-19 messenger RNA vaccine. Retin Cases Brief Rep
Pur DR, Catherine Danielle Bursztyn LL, Iordanous Y (2022) Branch retinal vein occlusion in a healthy young man following mRNA COVID-19 vaccination. Am J Ophthalmol Case Rep 26:101445
doi: 10.1016/j.ajoc.2022.101445
Park HS, Byun Y, Byeon SH et al (2021) Retinal hemorrhage after SARS-CoV-2 vaccination. J Clin Med 10(23):5705
doi: 10.3390/jcm10235705
Peters MC, Cheng SSH, Sharma A et al (2022) Retinal vein occlusion following COVID-19 vaccination. Clin Exp Ophthalmol. Ahead of print
Sonawane N, Yadav D, Kota A et al (2022) Central retinal vein occlusion post-COVID- 19 vaccination. Indian J Ophthalmol 70(1):308–309
doi: 10.4103/ijo.IJO_1757_21
Ikegami Y, Numaga J, Okano N et al (2022) Combined central retinal artery and vein occlusion shortly after mRNA-SARS-CoV-2 vaccination. QJM 114(12):884–885
doi: 10.1093/qjmed/hcab287
Lee S, Sankhala KK, Bose S et al (2022) Combined central retinal artery and vein occlusion with ischemic optic neuropathy after COVID-19 vaccination. Int Med Case Rep J 15:7–14
doi: 10.2147/IMCRJ.S328931
Abdin AD, Gärtner BC, Seitz B (2022) Central retinal artery occlusion following COVID-19 vaccine administration. Am J Ophthalmol Case Rep. 26:101430. https://doi.org/10.1016/j.ajoc.2022.101430
doi: 10.1016/j.ajoc.2022.101430
pubmed: 35198832
pmcid: 8855623
Greinacher A, Thiele T, Warkentin TE et al (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384(22):2092–2101
doi: 10.1056/NEJMoa2104840
Schultz NH, Sørvoll IH, Michelsen AE et al (2021) Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(22):2124–2130
doi: 10.1056/NEJMoa2104882
Scully M, Singh D, Lown R et al (2021) Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384(23):2202–2211
doi: 10.1056/NEJMoa2105385
Baker AT, Boyd RJ, Sarkar D, et al (2021) ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv 7(49):eabl8213
Greinacher A, Selleng K, Palankar R et al (2021) Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 138(22):2256–2268
doi: 10.1182/blood.2021013231
Muir KL, Kallam A, Koepsell SA et al (2021) Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Eng J Med 384:1964–1965
doi: 10.1056/NEJMc2105869
Simpson CR, Shi T, Vasileiou E et al (2021) First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med 27(7):1290–1297
doi: 10.1038/s41591-021-01408-4
Ng XL, Betzler BK, Testi I et al (2021) Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm 24:1–9
Jampol LM, Tauscher R, Schwarz HP (2021) COVID-19, COVID-19 vaccinations, and subsequent abnormalities in the retina: causation or coincidence? JAMA Ophthalmol 139(10):1135–1136
doi: 10.1001/jamaophthalmol.2021.3483
Vadalà M, Poddighe D, Laurino C, et al (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? 8(3):295–311